



ASX ANNOUNCEMENT

CELLMID APPOINTS DR DOMINIC BURG AS CHIEF OPERATING OFFICER

SYDNEY, Monday, 1 June 2020: Cellmid Limited (ASX: CDY) is pleased to advise that it has appointed Dr Dominic Burg as Chief Operating Officer (COO), effective 1 July 2020. A key member of the Cellmid executive team, Dominic joined the Company in March 2016 and has previously held positions as VP of Operations and Director of Operations.

Dominic has been instrumental in the Company's growth, fulfilling a broad mandate to improve operational efficiencies across Cellmid's consumer and biotechnology businesses. Expanding operations to the USA, Europe and Asia, Dominic has been a key driver of the evolis® consumer brand. A highly effective communicator, Dominic has built a culture of respect whilst improving professional performance of members of his team.

Prior to joining Cellmid Dominic received his PhD from the University of New South Wales and had an academic career spanning more than ten years. His post-doctoral appointments in Australia and abroad utilized his expertise in systems biology, and biomarkers of chronic and inflammatory diseases. During his academic career, Dominic worked in a public-private partnership with the pharmaceutical industry, running complex projects honing his analytical and strategic capabilities.

In his new role Dominic is very well placed to continue to leverage his strong scientific and strategic thinking in addition to his deep understanding of the Company's operations.

"Dominic is an exceptional professional with whom I had the pleasure of working for the past four years. He is highly respected by all of us at Cellmid, our employees, directors, and partners. I am very much looking forward to working with Dominic in a more strategic role" said CEO of Cellmid, Maria Halasz.

"The Company is fortunate indeed to have such an outstanding internal candidate for the important COO role, and Dominic's appointment ensures that we have the management depth and experience to deliver on our ambitious business plan" said Dr David King, Chairman of the Board.

"I am grateful for the opportunity and excited to continue to work with our team to deliver Cellmid's strategic objectives. I am particularly looking forward to driving operational profitability for our consumer business and growing our diagnostic assets" said COO-elect, Dr Burg.

Dr Dominic Burg is an author of several peer reviewed scientific publications and inventor of patents.

Approved for release by the Board of Directors.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830



@mariahalasz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with a consumer health business and biotech assets in development. Advangen is Cellmid's wholly owned subsidiary engaged in the development and sale of first in class, best in class, clinically validated anti-aging products for hair, skin and body. Advangen has a range of FGF5 inhibitor hair growth products which are sold in Australia, Japan, USA and China. Advangen has a rich portfolio of hair growth and anti-aging hair care assets which include formulations of products on market, trademarks, patents and patent applications, proprietary assays and manufacturing processes. For further information, please see www.cellmid.com.au and www.evolisproducts.com.au. Cellmid's wholly owned subsidiary, Lyramid, develops innovative novel therapies and diagnostic tests for age related diseases including inflammatory and autoimmune conditions. Lyramid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) globally. Most recently, the Company secured supply of diagnostic products for SARS-CoV-2.

Forward looking statements

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as the availability of resources, regulatory environment, the results of marketing and sales activities and competition.